Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Expectations By $1.45 EPS

Indaptus Therapeutics (NASDAQ:INDP) issued its quarterly earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.46) by $1.45, Zacks reports.

Indaptus Therapeutics Trading Up 0.7%

Indaptus Therapeutics stock traded up $0.02 during midday trading on Friday, reaching $3.17. The company’s stock had a trading volume of 80,802 shares, compared to its average volume of 588,617. Indaptus Therapeutics has a 52 week low of $0.92 and a 52 week high of $5.96. The business has a 50-day moving average price of $2.92 and a 200-day moving average price of $2.31. The stock has a market cap of $422.77 million, a PE ratio of -0.50 and a beta of 0.96.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways. The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease.